Class information for:
Level 2: GEFITINIB//EGFR MUTATION//MIDKINE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1717 6648 40.0 89%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
216 3       NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG 51214
1717 2             GEFITINIB//EGFR MUTATION//MIDKINE 6648
147 1                   GEFITINIB//EGFR MUTATION//ERLOTINIB 4147
5267 1                   CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK 1648
13215 1                   MIDKINE//PLEIOTROPHIN//HB GAM 853

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 GEFITINIB authKW 1398512 10% 45% 675
2 EGFR MUTATION authKW 1283819 6% 73% 385
3 MIDKINE authKW 1118683 4% 86% 284
4 ERLOTINIB authKW 1014019 8% 41% 545
5 CRIZOTINIB authKW 892074 4% 77% 254
6 ALK authKW 798154 5% 58% 301
7 NON SMALL CELL LUNG CANCER authKW 762604 19% 13% 1268
8 ANAPLASTIC LYMPHOMA KINASE authKW 663105 3% 66% 219
9 PLEIOTROPHIN authKW 626258 2% 82% 166
10 EGFR authKW 465788 11% 14% 742

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 100103 63% 1% 4171
2 Respiratory System 26775 17% 1% 1122
3 Pathology 4013 8% 0% 502
4 Cell Biology 979 8% 0% 547
5 Pharmacology & Pharmacy 498 8% 0% 515
6 Medical Laboratory Technology 422 2% 0% 105
7 Medicine, Research & Experimental 346 4% 0% 260
8 Chemistry, Medicinal 153 2% 0% 148
9 Biochemistry & Molecular Biology 123 9% 0% 579
10 Genetics & Heredity 88 3% 0% 203

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LOWE THORAC ONCOL 166867 1% 45% 80
2 GUANGDONG LUNG CANC 161377 1% 45% 78
3 THORAC ONCOL 139799 4% 12% 252
4 THORAC ONCOL SERV 112008 1% 35% 69
5 MED ONCOL 82831 14% 2% 919
6 THORAC SURG 43498 7% 2% 438
7 STATE SOUTH CHINA 40830 0% 68% 13
8 HEMATOL ONCOL P MED 38983 1% 23% 37
9 THORAC MED ONCOL 36742 0% 30% 27
10 PATHOL MOL DIAGNOST 36397 1% 17% 48

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF THORACIC ONCOLOGY 341306 7% 17% 446
2 LUNG CANCER 181107 6% 9% 418
3 CLINICAL LUNG CANCER 95825 2% 17% 126
4 THORACIC CANCER 23187 1% 10% 51
5 CLINICAL CANCER RESEARCH 16346 3% 2% 232
6 TARGETED ONCOLOGY 12789 1% 8% 34
7 ONCOTARGETS AND THERAPY 9439 1% 3% 63
8 ONCOTARGET 8527 2% 1% 153
9 JOURNAL OF CLINICAL ONCOLOGY 7840 3% 1% 169
10 LANCET ONCOLOGY 6434 1% 3% 51

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class		 LCSH search Wikipedia search
1 GEFITINIB 1398512 10% 45% 675 Search GEFITINIB Search GEFITINIB
2 EGFR MUTATION 1283819 6% 73% 385 Search EGFR+MUTATION Search EGFR+MUTATION
3 MIDKINE 1118683 4% 86% 284 Search MIDKINE Search MIDKINE
4 ERLOTINIB 1014019 8% 41% 545 Search ERLOTINIB Search ERLOTINIB
5 CRIZOTINIB 892074 4% 77% 254 Search CRIZOTINIB Search CRIZOTINIB
6 ALK 798154 5% 58% 301 Search ALK Search ALK
7 NON SMALL CELL LUNG CANCER 762604 19% 13% 1268 Search NON+SMALL+CELL+LUNG+CANCER Search NON+SMALL+CELL+LUNG+CANCER
8 ANAPLASTIC LYMPHOMA KINASE 663105 3% 66% 219 Search ANAPLASTIC+LYMPHOMA+KINASE Search ANAPLASTIC+LYMPHOMA+KINASE
9 PLEIOTROPHIN 626258 2% 82% 166 Search PLEIOTROPHIN Search PLEIOTROPHIN
10 EGFR 465788 11% 14% 742 Search EGFR Search EGFR

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , THUNNISSEN, E , LADANYI, M , LINDEMAN, NI , CAGLE, PT , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF THORACIC ONCOLOGY. VOL. 8. ISSUE 7. P. 823 -859 249 82% 228
2 LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF MOLECULAR DIAGNOSTICS. VOL. 15. ISSUE 4. P. 415 -453 247 82% 139
3 LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. VOL. 137. ISSUE 6. P. 828 -860 245 82% 138
4 MURAMATSU, T , (2011) MIDKINE: A PROMISING MOLECULE FOR DRUG DEVELOPMENT TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM.CURRENT PHARMACEUTICAL DESIGN. VOL. 17. ISSUE 5. P. 410-423 179 92% 39
5 MURAMATSU, T , (2010) MIDKINE, A HEPARIN-BINDING CYTOKINE WITH MULTIPLE ROLES IN DEVELOPMENT, REPAIR AND DISEASES.PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES. VOL. 86. ISSUE 4. P. 410 -425 150 91% 65
6 MIDHA, A , DEARDEN, S , MCCORMACK, R , (2015) EGFR MUTATION INCIDENCE IN NON-SMALL-CELL LUNG CANCER OF ADENOCARCINOMA HISTOLOGY: A SYSTEMATIC REVIEW AND GLOBAL MAP BY ETHNICITY (MUTMAPII).AMERICAN JOURNAL OF CANCER RESEARCH. VOL. 5. ISSUE 9. P. 2892 -+ 139 82% 13
7 OU, SHI , BARTLETT, CH , MINO-KENUDSON, M , CUI, J , IAFRATE, AJ , (2012) CRIZOTINIB FOR THE TREATMENT OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER: A SUCCESS STORY TO USHER IN THE SECOND DECADE OF MOLECULAR TARGETED THERAPY IN ONCOLOGY.ONCOLOGIST. VOL. 17. ISSUE 11. P. 1351 -1375 125 89% 82
8 MURAMATSU, T , (2002) MIDKINE AND PLEIOTROPHIN: TWO RELATED PROTEINS INVOLVED IN DEVELOPMENT, SURVIVAL, INFLAMMATION AND TUMORIGENESIS.JOURNAL OF BIOCHEMISTRY. VOL. 132. ISSUE 3. P. 359 -371 157 92% 214
9 HALLBERG, B , PALMER, RH , (2013) MECHANISTIC INSIGHT INTO ALK RECEPTOR TYROSINE KINASE IN HUMAN CANCER BIOLOGY.NATURE REVIEWS CANCER. VOL. 13. ISSUE 10. P. 685-700 133 65% 106
10 PAO, W , CHMIELECKI, J , (2010) RATIONAL, BIOLOGICALLY BASED TREATMENT OF EGFR-MUTANT NON-SMALL-CELL LUNG CANCER.NATURE REVIEWS CANCER. VOL. 10. ISSUE 11. P. 760-774 109 69% 403

Classes with closest relation at Level 2


Rank Class id link
1 1422 XRCC1//GEMCITABINE//ERCC1
2 2452 HEPATOCYTE GROWTH FACTOR//C MET//HGF
3 3290 HAND FOOT SYNDROME//HYPERSENSITIVITY REACTION//RADIATION RECALL
4 652 HER2//TRASTUZUMAB//HER 2 NEU
5 1979 BRAIN METASTASES//BRAIN METASTASIS//WHOLE BRAIN RADIOTHERAPY
6 337 THORAC SURG//LUNG CANCER//RESPIRATORY SYSTEM
7 1071 LYNCH SYNDROME//MICROSATELLITE INSTABILITY//HNPCC
8 1452 CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB
9 1101 BIOINFORMATICS//COPY NUMBER VARIATION//NEXT GENERATION SEQUENCING
10 1612 SMALL CELL LUNG CANCER//BOMBESIN//GASTRIN RELEASING PEPTIDE

Go to start page